Search clinical trials for: SEL-068

Total 8265 results

Shanghai Antengene Corporation Limited

Terminated

A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)

Advanced Solid Tumors

China
Swedish Orphan Biovitrum

Completed

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy (DISSOLVE I)

Chronic Gout

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Selecta Biosciences, Inc.
National Human Genome Research Institute (NHGRI)

Suspended

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA (reiMMAgine)

Methylmalonic Acidemia (MMA)

United States
ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd

Recruiting

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Australia
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Terminated

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Thailand, Malaysia, Korea, Republic of, Italy, United Kingdom, Poland, Germany, Turkey
AbbVie

Completed

A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Psoriasis

Japan
Takeda

Completed

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

Schizophrenia

United States
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Non Hodgkin Lymphoma

China
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) (LIMMITLESS)

Psoriasis

United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Germany, Japan, Korea, Republic of, Mexico, Poland, Portugal, Spain, Sweden, Taiwan
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Completed

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

Duchenne Muscular Dystrophy

Korea, Republic of, Chile, Taiwan, China, United States, United Kingdom, Netherlands, Spain, Australia, Norway, Russian Federation, Greece, Italy, Turkey, Mexico, Canada, Hong Kong, New Zealand, Ukraine
AbbVie

Completed

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis

United States, Australia, Canada, Japan, Puerto Rico
AbbVie

Terminated

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
AbbVie

Completed

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Psoriatic Arthritis
Genentech, Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain
Travere Therapeutics, Inc.

Enrolling by invitation

A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

Homocystinuria

United States
CSL Behring

Completed

Dose Confirmation Trial of AAV5-hFIXco-Padua

Hemophilia B

United States
LaNova Medicines Limited

Terminated

Study of LM-061 in Subjects in Advanced Tumors

Advanced Tumours

Australia
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Completed

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

Duchenne Muscular Dystrophy

Spain, United States, Russian Federation, Italy, China, Turkey
Antengene Corporation

Terminated

A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (MATCH)

Relapsed/Refractory Diffuse Large B-cell Lymphoma

China
AbbVie

Completed

Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

Japan
AbbVie

Completed

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

Healthy Volunteers

United States
Purdue University
Mushroom Council

Completed

Mushroom Ingestion Study

Diet, Healthy

United States
Ahmed A. H. Abdellatif

Unknown

Topical Silver Nanoparticles for Microbial Activity

Infection, Bacterial | Foot Infection Fungal

Saudi Arabia
Kerti Praja Foundation
United Nations

Unknown

Community Based Screening for HIV Self Testing in FSW in 23 Priority Districts in Indonesia (CBS-FSW)

Human Immunodeficiency Virus (HIV)

Indonesia
Moon (Guangzhou) Biotechnology Co., Ltd.

Not yet recruiting

Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor (MNC-168)

Advanced Malignant Solid Tumors
Chr Hansen

Completed

Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population

Inflammation

Ireland
Selecta Biosciences, Inc.

Completed

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

Hyperuricemia | Gout Chronic

United States
AO GENERIUM

Completed

Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers

Hereditary Angioedema

Russian Federation
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Optimapharm

Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Gastrointestinal Cancer

Germany
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Non-hodgkin's Lymphoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Primary Central Nervous System Lymphoma | Secondary Central Nervous System Lymphoma

China
ChemRar Research and Development Institute, LLC

Not yet recruiting

A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

Anxiety Disorder Generalized
AbbVie
Boehringer Ingelheim

Completed

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AltruBio Inc.
ICON plc

Completed

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

Healthy Volunteers

United States
Invicro

Completed

D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562

Healthy Male Volunteers

United States
Prove pharm

Not yet recruiting

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients

Ureter Injury
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

China
Eli Lilly and Company

Completed

A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of the Effects of LY3372689 on the Brain in Healthy Participants

Healthy

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Takeda

Active, not recruiting

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Celiac Disease

United States, Belgium, Poland, Italy, Canada, United Kingdom, France, Spain
Prove pharm

Recruiting

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency

Ureter Injury

United States
Sichuan University

Recruiting

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

Advanced Solid Tumor

China
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Purdue Pharma, Canada

Completed

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD

United States
Gilead Sciences

Completed

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease (MOSAIC)

Diabetic Kidney Disease

United States, Japan, New Zealand, Australia, Canada
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR-3)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Spain, United Kingdom, Australia, Taiwan, Belgium, Canada, India, Japan, Korea, Republic of, Singapore, Puerto Rico, France, Israel, Austria, Germany, Italy, Malaysia, New Zealand, Mexico, Poland, Switzerland, Netherlan... and more
AltruBio Inc.

Recruiting

Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Ulcerative Colitis

United States, Canada
Emergent BioSolutions
United States Department of Defense

Completed

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults

SARS-CoV-2 Infection

United States

3

Subscribe